Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Endometrial Neoplasms 12Polycystic Ovary Syndrome 4Endometrial Hyperplasia 4Infertility 3Neoplasms 2Anovulation 2Vitamin D Deficiency 1Turcot syndrome 1Overweight 1Obesity 1Menorrhagia 1Leiomyoma 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Endometrioid 1Breast Neoplasms 1Advanced, Persistent, or Recurrent Endometrial Cancer 1Adenocarcinoma 1

Interventions

telapristone acetate 18ulipristal acetate 17Uterine Myomectomy 13vilaprisan 12Leuprolide 11relugolix 9estradiol, norethindrone drug combination 9asoprisnil 9elagolix 7Uterine Artery Embolization 7Mifepristone 7Estradiol 7Bupivacaine 7ulipristal 6Tranexamic Acid 6Saline Solution 5Norethindrone Acetate 5linzagolix 4epigallocatechin gallate 4Sodium Chloride 4Letrozole 4Hysterectomy 4Vitamin B 6 3Sugars 3Misoprostol 3Lidocaine 3Gonadotropin-Releasing Hormone 3Embolization, Therapeutic 3cetrorelix 2Vitamin D 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Leiomyoma × Medroxyprogesterone Acetate × Clear all
NCT06671548 2026-02-02

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
120 enrolled

Leiomyoma, Menorrhagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡